{"id":403878,"date":"2025-06-24T10:23:31","date_gmt":"2025-06-24T08:23:31","guid":{"rendered":"https:\/\/medizinonline.com\/les-patientes-atteintes-dun-cancer-de-lovaire-resistant-au-platine-beneficient-dune-nouvelle-autorisation-de-mise-sur-le-marche\/"},"modified":"2025-06-24T10:28:45","modified_gmt":"2025-06-24T08:28:45","slug":"les-patientes-atteintes-dun-cancer-de-lovaire-resistant-au-platine-beneficient-dune-nouvelle-autorisation-de-mise-sur-le-marche","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/les-patientes-atteintes-dun-cancer-de-lovaire-resistant-au-platine-beneficient-dune-nouvelle-autorisation-de-mise-sur-le-marche\/","title":{"rendered":"Les patientes atteintes d&#8217;un cancer de l&#8217;ovaire r\u00e9sistant au platine b\u00e9n\u00e9ficient d&#8217;une nouvelle autorisation de mise sur le march\u00e9"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Le cancer de l&#8217;ovaire r\u00e9sistant au platine (PROC) repr\u00e9sente un d\u00e9fi th\u00e9rapeutique majeur &#8211; les options de traitement limit\u00e9es et les mauvais pronostics restent malheureusement une r\u00e9alit\u00e9 [1]. Cependant, un progr\u00e8s important se dessine avec l&#8217;approbation du conjugu\u00e9 anticorps\/principe actif (ADC) mirvetuximab soravtansine [2, 3]. Viola Heinzelmann-Schwarz, de l&#8217;H\u00f4pital universitaire de B\u00e2le, le Dr Ilaria Colombo, de l&#8217;Ente Ospedaliero Cantonale, le PD Dr Marcus Vetter, de l&#8217;H\u00f4pital cantonal de B\u00e2le-Campagne, et le Dr Gabriela Grimaldi, de l&#8217;Ente Ospedaliero Cantonale, ont discut\u00e9 de ce qu&#8217;il faut savoir sur le traitement et analys\u00e9 son importance pour les personnes concern\u00e9es. Consultez l&#8217;entretien ici !   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fles-patientes-atteintes-dun-cancer-de-lovaire-resistant-au-platine-beneficient-dune-nouvelle-autorisation-de-mise-sur-le-marche%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Le cancer de l&#8217;ovaire r\u00e9sistant au platine (PROC) repr\u00e9sente un d\u00e9fi th\u00e9rapeutique majeur &#8211; les options de traitement limit\u00e9es et les mauvais pronostics restent malheureusement une r\u00e9alit\u00e9 [1]. Cependant, un&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fles-patientes-atteintes-dun-cancer-de-lovaire-resistant-au-platine-beneficient-dune-nouvelle-autorisation-de-mise-sur-le-marche%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":14,"featured_media":403879,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Contenu sponsoris\u00e9 : Vid\u00e9o - Table ronde d'experts","footnotes":""},"category":[11389,11523,11345,11531,12075,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-403878","post","type-post","status-publish","format-standard","has-post-thumbnail","category-oncologie","category-actualites","category-contenu-des-partenaires","category-formation-continue","category-formation-continue-avec-partenaire","category-rx-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-06 02:49:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/403878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=403878"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/403878\/revisions"}],"predecessor-version":[{"id":403880,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/403878\/revisions\/403880"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/403879"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=403878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=403878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=403878"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=403878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}